CDC Not Testing For Pox Viruses Amid Mpox Outbreaks, Treatment Concerns

Why It Matters

Without reliable diagnostics, public health officials cannot accurately track or contain mpox spread, and clinicians lack confidence in first‑line therapy, potentially worsening outbreaks and straining health systems.

Key Takeaways

• CDC halted testing for smallpox, mpox, rabies
• Mpox cases rising in multiple countries
• First-line antiviral tecovirimat efficacy questioned
• Testing gap hampers surveillance and outbreak response
• Public health agencies urged to restore diagnostics

Pulse Analysis

The CDC’s decision to suspend testing for pox viruses marks a stark shift in America’s infectious‑disease surveillance framework. Historically, laboratory confirmation has been the backbone of outbreak detection, enabling rapid public‑health interventions. By pulling smallpox, mpox and rabies assays from its portfolio, the agency leaves clinicians to rely on external labs, which often have longer turnaround times and variable quality. This move comes at a time when mpox is resurging across Europe, Africa and parts of the Americas, creating blind spots that could delay containment measures.

Compounding the diagnostic void, recent clinical observations suggest that tecovirimat, the antiviral approved for mpox, may no longer guarantee cure rates seen in earlier outbreaks. Preliminary resistance patterns hint at viral mutations that diminish drug binding, prompting physicians to consider off‑label therapies with less established safety profiles. The uncertainty around treatment efficacy fuels hesitancy among patients and providers, potentially increasing transmission as cases go untreated or are mismanaged. Moreover, insurers and health systems face budgeting challenges when alternative, often more expensive, therapeutics are required.

Policy experts argue that restoring comprehensive pox‑virus testing should be a priority for the CDC and state health departments. Investing in multiplex PCR platforms and expanding the Laboratory Response Network would close the diagnostic gap and provide real‑time data for epidemiologists. Such infrastructure not only supports mpox control but also bolsters preparedness for any future orthopoxvirus threats, including bioterrorism scenarios. Aligning diagnostic capacity with updated treatment guidelines will improve patient outcomes, reduce outbreak costs, and reinforce confidence in the nation’s public‑health response.